Astellas Pharma, Inc.

Bayer’s hopes of launching elinzanetant onto the US market this summer have been dashed by the US Food and Drug Administration which needs more to time to evaluate the company’s submission for the clo

The pharmaceutical market is notoriously difficult to predict. Drug developers and the analysts who cover them must navigate a landscape shaped by geopolitical shifts, financial pressures and regulato

Bayer has secured the first global approval for elinzanetant, trumpeted as a key growth driver for its pharma division in the coming years, after the UK gave the green light to the hot flashes therapy

Contract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet